Traditionally, HR+ breast cancer has been classified as immunologically “cold” due to its low PD-L1 expression, reduced tumor-infiltrating lymphocytes, and low tumor mutational burden, collectively limiting immunotherapy responsiveness. Here, CD274 is linked to breast carcinoma.